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Abstract
Background Follicular lymphoma (FL) prognosis is influenced by the composition of the tumour microenvironment. We 
tested an automated approach to quantitatively assess the phenotypic and spatial immune infiltrate diversity as a prognostic 
biomarker for FL patients.
Methods Diagnostic biopsies were collected from 127 FL patients initially treated with rituximab-based therapy (52%), 
radiotherapy (28%), or active surveillance (20%). Tissue microarrays were constructed and stained using multiplex immuno-
fluorescence (CD4, CD8, FOXP3, CD21, PD-1, CD68, and DAPI). Subsequently, sections underwent automated cell scoring 
and analysis of spatial interactions, defined as cells co-occurring within 30 μm. Shannon’s entropy, a metric describing species 
biodiversity in ecological habitats, was applied to quantify immune infiltrate diversity of cell types and spatial interactions. 
Immune infiltrate diversity indices were tested in multivariable Cox regression and Kaplan–Meier analysis for overall (OS) 
and progression-free survival (PFS).
Results Increased diversity of cell types (HR = 0.19 95% CI 0.06–0.65, p = 0.008) and cell spatial interactions (HR = 0.39, 
95% CI 0.20–0.75, p = 0.005) was associated with favourable OS, independent of the Follicular Lymphoma International 
Prognostic Index. In the rituximab-treated subset, the favourable trend between diversity and PFS did not reach statistical 
significance.
Conclusion Multiplex immunofluorescence and Shannon’s entropy can objectively quantify immune infiltrate diversity and 
generate prognostic information in FL. This automated approach warrants validation in additional FL cohorts, and its appli-
cability as a pre-treatment biomarker to identify high-risk patients should be further explored. The multiplex image dataset 
generated by this study is shared publicly to encourage further research on the FL microenvironment.
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Introduction
In follicular lymphoma (FL) there is a clinical need for 
pre-treatment identification of high-risk patients, recog-
nisable as the subset of patients (15–30%) with early pro-
gression and poor survival outcomes despite therapeutic 
advances [1–3]. Current FL prognostic biomarkers, such as 
the Follicular Lymphoma International Prognostic Index 
(FLIPI) [4, 5], are well validated but lack the necessary 
precision for clinical decision-making. To improve risk 
stratification, subsets of tumour-infiltrating lymphocytes 
(TILs) have been studied, but there is no consensus on the 
observed effect [1, 6–8]. Immune subsets of prognostic 
interest include, among others:  CD68+ lymphoma-asso-
ciated macrophages [9–12],  CD3+ T cells [10, 12–14], 
 CD4+ T helper cells [12–14],  CD8+ cytotoxic T cells 
[12–15],  CD4+FOXP3+ T regulatory cells (Tregs) [12, 14, 
16–18],  CD21+ dendritic cells [12], mast cells [19], and 
PD-1 expressing T-cells [12, 14, 20]. These cells engage 
in crosstalk through multiple pathways [21], and therefore 
a holistic observation of immune infiltrate diversity could 
be more informative than examining isolated components.
In ecological sciences the Shannon diversity (or 
entropy) index quantifies biodiversity in terms of “even-
ness” [22]. For example, if three species are found in an 
area, and one accounts for 99% of the population, this 
community would be considered less diverse than one 
where the three species are found in approximately equal 
abundances. Entropy is calculated from the proportion of 
each species in the community and increases when diver-
sity is higher. It has found applications in histopathology 
to quantify heterogeneity of HER2 expression [23] and 
chromosome 8q24 copy number variation [24] in breast 
cancer. If we consider each cell phenotype as a species, 
this metric can be applied to quantify immune infiltrate 
diversity.
Similarly, it is possible to quantify the diversity of not 
only phenotypes but also their spatial interactions, which 
is recognised for its potential as a biomarker [25] for many 
tumour types including FL [16, 26]. The hypothesised 
interactions distribution (HID) method [27] can identify 
spatial interactions defined as co-occurrences of different 
cell types within 30 μm. The diversity of these spatial 
interactions can also be investigated using entropy.
We aimed to develop a methodology to quantitatively 
assess immune infiltrate diversity in the tumour microenvi-
ronment of FL and test its potential utility as a prognostic 
biomarker. To this end, an automated multiplex immuno-
fluorescence and image analysis pipeline were developed 
to simultaneously identify cells positive for CD4, CD68, 
CD8, CD21, FOXP3, and PD-1. We show that increased 
diversity of immune infiltrate populations and interactions 
is associated with improved overall survival (OS) in a 




The study was conducted with approval from the 
North–West Multi-centre Ethics Committee (03/08/016), 
according to the Declaration of Helsinki. Examination 
of 350 FL patients’ electronic records in a random order 
from the archives of The Christie NHS Foundation Trust, 
Manchester, UK, identified 262 patients meeting the inclu-
sion criteria: adult; diagnosed from incisional or excisional 
biopsy; non-primary cutaneous; and treated at first presen-
tation with radiotherapy, watchful waiting, or rituximab-
based systemic therapy. Pre-treatment diagnostic biopsies 
were requested for 262 patients, of which 131 had sufficient 
tissue. The 131 patients were diagnosed between 1998 
and 2015, with a median follow-up of 114 months (range 
3–199 months). Histological diagnosis of FL was re-con-
firmed by an expert haemato-pathologist (R.B). Regions 
of interest were identified by the haemato-pathologist, and 
cores were extracted in triplicate from formalin-fixed, paraf-
fin-embedded (FFPE) blocks to construct five tissue micro-
arrays (TMA). Core diameter was 1.2 mm. Follicular and 
extrafollicular regions were both selected for inclusion in the 
TMA. A section of each TMA stained with H&E is provided 
[28], to demonstrate the morphology of selected regions. 
Some cores were excluded because of poor quality, leaving 
349 cores from 130 patients. The OS distribution was similar 
between the 130-patient cohort and the patients with insuf-
ficient tumour material (Supplementary Fig. 1, log rank test 
p = 0.37). Furthermore, three patients with FL grade 3b were 
excluded from survival analyses, as their disease progression 
and treatment pathways resemble more closely Diffuse Large 
B-cell Lymphoma and grade 3b FL is generally considered 
a separate disease entity [29]. Finally, 342 cores from 127 
patients remained available for further analyses.
Clinical endpoints
OS was recorded for all patients (N = 127). Progression-free 
survival (PFS) and disease progression within 24 months of 
starting treatment (POD24) were recorded only for patients 
treated with rituximab-containing immuno-chemotherapy at 
first presentation (N = 67). The events of disease progres-
sion and relapse were defined using the Lugano criteria [30]. 
PFS was calculated from diagnosis until the first observed 
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progression event (or disease-specific death) or, if no events 
were observed, until the date of last follow-up.
Multiplex immunofluorescence imaging
In this section we describe preparation of the image data-
set using multiplex immunofluorescence and multi-spectral 
scanning.
Antibody panel selection
A panel of antibodies was selected to identify non-neoplastic 
immune infiltrate subsets. CD68 was selected to observe 
monocytic cells and particularly macrophages [10, 11]. CD8 
was used to observe cytotoxic T cells  (CD8+) [8]. T helper 
cells were identified by inclusion of the CD4 marker, as the 
subset that expressed CD4, but not CD68 [8]. Additionally, 
FOXP3 was used to identified T regulatory cells (Tregs 
 [CD4+FOXP3+]) [26]. The CD21 marker was used to iden-
tify follicular dendritic cell areas [31]. While CD21 might 
also be expressed in B-cells, follicular dendritic cells in fol-
licular lymphoma can be identified by their characteristic 
meshwork staining pattern [32]. PD-1 detected  CD4+PD-1+ 
T follicular helper cells and  CD8+PD-1+ lymphocytes [20]. 
Finally, DAPI (4′,6-diamidino-2-phenylindole) was the 
nuclear counterstain. No B-cell tumour marker was used, 
as we aimed to study the diversity of the non-neoplastic 
microenvironment.
Staining protocol
A single 4-μm section was cut from each of the five TMAs 
of the cohort. These sections were stained with a 6-plex 
immunofluorescent assay using tyramide signal amplifica-
tion, the Opal 7 colour kit (Akoya Biosciences, CA, USA), 
and the Ultra Discovery auto-stainer (Roche, Switzerland), 
as described in the experimental protocol of Tsakiroglou 
et al. [33], and are summarised in Supplementary Table 1. 
The OPAL detection system allows for repeated cycles of 
staining and stripping of anti-mouse and anti-rabbit antibod-
ies. In each cycle, the primary antibody and secondary con-
jugated to horseradish peroxidase (HRP) are incubated on 
the tissue, followed by fluorophore-labelled tyramide. The 
catalytic reaction that occurs binds the fluorophore strongly 
on the tissue epitopes. Thereafter, heat stripping is applied 
to remove the antibody before applying the next one, but the 
fluorophores remain on the tissue. We quantitatively vali-
dated good agreement between single-plex and multiplex 
immunofluorescent assays (Supplementary Material Sect. 2, 
Supplementary Fig. 2–5).
Image acquisition
Stained sections were scanned with the Vectra 3.5 micro-
scope (Akoya Biosciences). Initially, a low-resolution scan 
(10x) was performed to manually annotate the TMA core 
locations. Then, a multi-spectral image of each core was 
acquired at 20 × magnification (0.49 μm/pixel). Spectral 
unmixing [34] was performed using inForm 2.4 software 
(Akoya Biosciences). To separate the fluorophore signals, 
a spectral library was pre-built; the individual spectrum of 
each fluorophore, DAPI, and auto-fluorescence was acquired 
from single-plex controls. After unmixing, the images con-
sisted of 6 channels, each containing the intensities of a dif-
ferent fluorophore, plus two channels for DAPI and auto-
fluorescence ( 2420 × 2420 × 8 pixels). All prepared images 
(example in Fig. 1) are publicly available at http:// dx. doi. 




Nuclear detection in these images was challenging, because 
of densely packed and overlapping cells. Therefore, label-
free cell detection, as offered by inForm software, was 
insufficient. Instead, we trained a deep learning model on 
the DAPI channel using the “StarDist” method [35] (code 
available: https:// github. com/ mpicbg- csbd/ stard ist). The 
model was trained on 67,991 nuclear outline annotations, 
was fine-tuned using an additional validation set of 906 
nuclei, and achieved average precision of 83% when tested 
on 883 unseen nuclei. The training, validation, and test sets 
were created for the purpose of this study by a trained non-
expert, under supervision from a pathologist (R.B.). More 
details on the performance validation can be found in the 
supplementary material (Supplementary Material Sect. 3, 
Supplementary Fig. 6, and Supplementary Table 2). The 
nuclear annotations are publicly available (http:// dx. doi. org/ 
10. 17632/ nb46s 9trx3.1). After nuclear detection, simulated 
membranes were grown around the nuclei by maximum 
1.5 μm to represent whole cells (Supplementary Fig. 7) and 
measurements are taken of the median intensity for all stains 
and each cell compartment (nucleus, membrane).
Cell scoring
A single threshold was selected to mark positive cells 
for each stain across the entire dataset by observing 
the median stain intensity on the relevant compartment 
(nucleus for FOXP3 and membrane for all others). To 
select positivity thresholds, two annotators examined 10 
multiplex images (Supplementary Material Sect. 4 and 
3576 Cancer Immunology, Immunotherapy (2021) 70:3573–3585
1 3
Supplementary Table 3), and the average threshold values 
were chosen. Cell density was subsequently measured for 
each cell phenotype of interest by dividing the number of 
positive cells by the tissue area.
When testing the prognostic significance of individual 
cell subsets, the total number of cells expressing a stain were 
observed to facilitate comparisons with prior FL studies. For 
example, when observing the cell subset that expressed CD68, 
Fig. 1  Multiplex immunofluo-
rescence and automated image 
analysis to measure immune 
infiltrate diversity. a Is a 
composite multiplex image dis-
playing all stains together using 
pseudo-colours: DAPI is blue, 
CD21 is red, CD4 is orange, 
PD-1 is cyan, CD8 is yellow, 
CD68 is magenta, and FOXP3 
is green. Panels (b-i) and (k-l) 
show the exact same tissue 
region, indicated as a white rec-
tangle in (a). Panels (b-i) dem-
onstrate the process of spectral 
unmixing: b shows DAPI in 
white; c shows CD21 in red; d 
shows CD4 in orange; e shows 
PD-1 in cyan; f shows CD4 
(orange) and PD-1 (cyan) over-
laid to show that PD-1 mostly 
almost always colocalised with 
CD4 in follicular regions; g 
shows CD68 in magenta; h 
shows FOXP3 in green; i shows 
CD8 in yellow. j Summarises 
the methodology. Panels (k-l) 
demonstrate the process of 
observing spatial interactions: k 
shows FOXP3 (green) and CD8 
(yellow) stains overlaid; l shows 
spatial “interactions” between 
cells scored as  FOXP3+ (shown 
in red) and  CD8+ (shown in 
yellow) are plotted as connec-
tions (shown in white) between 
cells occurring within 30 μm of 
each other
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all  CD68+ cells were counted, regardless of the expression of 
other markers. In this way, the findings can be compared with 
previous FL studies that used single-plex assays to observe the 
prognostic value of CD68 stain [9–12].
Total immune infiltrate ratio
Additionally, the total immune infiltrate was measured as the 
number of cells expressing any of the CD4, FOXP3, CD8, 
CD68, or PD-1 markers. The immune infiltrate ratio was sub-
sequently calculated by dividing the immune infiltrate cells by 
the number of all non-immune cells that expressed only DAPI. 
This ratio can be used to represent the extent of total immune 
infiltration in the microenvironment of FL.
Identifying CD21+ follicular dendritic meshwork areas
To quantify the extent of  CD21+ follicular dendritic mesh-
work areas, manual annotations were drawn around them for 
all samples (Supplementary Fig. 8), under supervision of a 
pathologist. Subsequently, the area covered by these meshwork 
patterns was measured and expressed as a proportion of the 
total tissue area.
Quantifying diversity of immune infiltrate
The next section introduces a method to objectively quan-
tify the diversity of the non-neoplastic immune microenvi-
ronment. The cell types studied in the diversity analyses 
were not predetermined. Instead, all five different stains 
(CD4, CD8, CD68, FOXP3, PD-1) were observed for cell 
phenotyping. Each possible combination of stain expres-
sion was regarded as a distinct phenotype. As an example, 
 CD4+CD8−CD68−FOXP3+PD-1− was considered distinct 
from  CD4+CD8−CD68−FOXP3+PD-1+. In this categorisation 
there exists a total of 25 = 32 stain positivity combinations, 
and each cell can only belong to a single phenotype. Cells 
expressing none of these markers were not included in the 
diversity analysis, as the aim was to assess the diversity of the 
non-neoplastic immune tumour microenvironment. Therefore, 
cells positive only for DAPI or only for CD21 were excluded 
as these could potentially include FL B-cell subsets.
Immune infiltrate diversity quantification
Immune infiltrate diversity was assessed by computing Shan-







where N is the number of all possible cell phenotypes and pi 
the proportion of each phenotype i in a sample.
Diversity of spatial interactions
The diversity of spatial interactions in each sample was addi-
tionally quantified by applying the HID methodology [27]. 
HID performs a pair-wise examination of cell types identi-
fied during cell scoring and counts their spatial interactions, 
i.e. their frequency of co-occurrence within a pre-specified 
distance (see Fig. 1k–l). Further implementation details can 
be found in Rose et al. [27]. The distance parameter was 
selected as 30 μm similar to the study of Tsakiroglou et al. 
[36], which represents a neighbourhood of 3–4 cells. A co-
occurrence between each pair of phenotypes i and j was 
considered a unique type of spatial interaction. The propor-
tion of all interactions belonging to this type  pi,j could then 
be calculated. If we consider each type of interaction as a 
separate “species”, Shannon’s entropy diversity index for 
the distribution of interactions in a sample can be derived:
In the current study all N phenotypes that were observed 
in the samples across the entire dataset were assessed, while 
cells expressing only DAPI were ignored. Intuitively, inter-
action entropy quantifies the diversity of co-occurrences 
between immune cell subsets.
A summary of the methodology steps is given in Fig. 1j.
Statistical analysis
A patient flow chart for the analyses is presented in Fig. 2. 
Since cores were extracted in triplicate for each patient, the 
median feature value was used to represent the patient. Uni-
variable analysis for OS and PFS was carried out using Cox 
regression models, where all features were treated as con-
tinuous variables. Multivariable analysis involved building 
Cox regression models to assess associations, independent 
of FLIPI. FLIPI was assessed as an ordinal score 0–5 [4]. 
FLIPI was selected for multivariable analyses as a state-of-
the-art, widely validated prognostic index. We did not test 
histologic grade in multivariable analyses as its prognostic 
value for FL is limited and patients with grade 1–2 and 3a 
have similar survival rates [37–39].
Kaplan–Meier analysis for the diversity features was 
carried out by dichotomising the variables at the optimal 
cut point. This cut point was selected to maximise the dif-
ference in survival characteristics between the groups, and 
an adjusted p value was provided to account for bias using 
the Contal and O’Quigley method [40]. The findcut imple-
mentation in SAS 9.4 was used for this optimal cut-point 
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selection [41]. Confidence intervals were calculated in 
Kaplan–Meier analysis using Greenwood’s formula [42].
Differences between POD24-positive and POD24-
negative groups were tested using the nonparametric 
Mann–Whitney U test. Univariable and multivariable 
logistic regression was also applied for POD24 predic-
tion. All patients included in POD24 analyses had at least 
24 months of follow-up.
Significance was assessed at a level α = 0.05, and the 
Bonferroni correction was applied to account for multiple 
hypothesis testing. Statistical tests were performed using 
the lifelines v.0.14.6, statsmodels v.0.10.1, and scipy 
v.1.3.1 libraries in Python.
Results
Cohort characteristics
The 127 FL patients were initially treated with rituximab-
based therapy (52%), radiotherapy (28%), or active surveil-
lance (20%). The 3- and 5-year OS rates were 97.7% (95% 
CI: 92.67, 99.22) and 94.46% (95% CI: 88.51, 97.14). For 
POD24 analysis, 67 patients had a minimum of 2-year 
follow-up, and 14 had an observed progression event 
within 24 months of the initiation of immuno-chemother-
apy (20.3%). POD24 was an indicator of unfavourable OS 
Fig. 2  Flow chart of patients in 
the study. OS indicates overall 
survival; PFS progression-free 
survival and POD24 disease 
progression within 24 months 
of starting treatment
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(p = 0.001) and PFS (p < 0.001) (Supplementary Fig. 9). 
FLIPI data were available at diagnosis for 101 patients, 
of which 51 were treated with rituximab-based regimens. 
FLIPI takes into account age, stage, haemoglobin levels, 
lactate dehydrogenase (LDH) levels, and number of nodal 
site involvement. The distribution of FLIPI index risk 
(low: 44%, intermediate: 33%, high: 23%) is similar to 
that reported by others [5].
Supplementary Table 4 summarises all patient charac-
teristics at diagnosis, and Supplementary Material Sect. 8 
describes the prognostic value of clinical characteristics 
commonly used to assess patient risk (e.g. FLIPI) in uni-
variable Cox regression analysis (Supplementary Table 5).
Distribution of immune cell densities and diversity 
metrics
Supplementary Table 6 provides the median, inter-quartile 
range, and intra-patient coefficient of variation (CoV) of cell 
populations and diversity metrics in the 127-patient cohort. 
The CoV measures intra-patient heterogeneity between 
different TMA cores for the same patient. The CoV of the 
diversity metrics was very low (7.7% and 8.3% for interac-
tion and phenotype entropy, respectively), indicating that 
diversity in FL could be accurately measured by use of trip-
licate core samples.
Cell population densities were not prognostic 
in multivariable analysis
In univariable Cox regression for OS, only the density of 
macrophages (HR = 0.99, 95% CI 0.98, 1.0) was significant 
after the Bonferroni correction for multiple comparisons 
(Table 1). However, in univariable Cox regression for PFS 
(Table 1), and all multivariable analyses (Table 2), none of 
the cell population densities were statistically significant.
Increased total immune infiltrate was seen 
in patients without POD24
Higher density of several immune subsets was seen in 
the group without POD24 (Fig. 3), and an increased total 
immune infiltrate ratio was significantly favourable for 
POD24 after Bonferroni adjustments. However, none of 
features remained significantly correlated with POD24 in 
univariable or multivariable logistic regression analyses 
(Table 3).
Immune infiltrate diversity analysis
Increased diversity of cell types (HR = 0.22, 95% CI 0.07, 
0.64) and diversity of spatial interactions (HR = 0.47, 95% 
CI 0.27, 0.82) were favourable for OS in univariable Cox 
regression analysis (N = 127, Table 1). Furthermore, in 
multivariable Cox regression analysis (N = 101, Table 2), 
the diversity of spatial interactions was favourable for OS 
(HR = 0.39, 95% CI 0.20, 0.75) and remained significant 
after Bonferroni correction. Therefore, the immune diversity 
biomarker offers prognostic value which is independent of 
FLIPI.
Kaplan–Meier analysis showed a trend towards increased 
diversities being favourable for OS (Fig. 4), when stratified 
at the optimal cut-off. The optimal cut-off was selected using 
the Contal & O’ Quigley [41] method, where all possible 
Table 1  Univariable survival analysis for features derived from the tumour microenvironment
HR hazard ratio; CI confidence intervals; PH proportional hazards; OS overall survival; PFS progression-free survival. *The log rank test p 
value examines whether the null hypothesis of no effect  (H0: HR = 1) can be rejected. †Immune infiltrate ratio is calculated as the total immune 
cells (positive for any marker) divided by the number of cells that expressed only DAPI. P values ≤ 0.05 are shown in bold. All features were 
assessed as continuous variables. P values ≤ 0.005 remain significant after the Bonferroni correction for multiple hypothesis testing
Univariable Analysis Cox PH Univariable OS All Patients, 
N = 127, 27 Events
Cox PH Univariable PFS 
Rituximab Patients, N = 67, 39 
Events
HR (95% CI) P* HR (95% CI) P*
Cell density, cells/mm2 CD4+CD68− T-helper cells 1 (1, 1) 0.264 1 (1, 1) 0.160
CD4+FOXP3+ T-regs 0.96 (0.92, 0.99) 0.023 0.97 (0.95, 1) 0.022
CD8+ T-cells 0.99 (0.99, 1) 0.055 1 (0.99, 1) 0.211
CD68+ cells 0.99 (0.98, 1) 0.002 0.99 (0.99, 1) 0.010
CD4+CD68−PD-1+ 0.99 (0.98, 1.01) 0.278 1 (0.99, 1.01) 0.467
CD8+PD-1+ 0.97 (0.94, 1) 0.084 0.99 (0.97, 1.01) 0.253
Cell ratio Immune infiltrate ratio† 0.21 (0.05, 0.92) 0.039 0.25 (0.08, 0.82) 0.023
% Positive area CD21+ dendritic meshwork area 1.65 (0.31, 8.8) 0.556 1.35 (0.41, 4.48) 0.626
Diversity, natural digits Phenotype entropy 0.22 (0.07, 0.64) 0.006 0.69 (0.3, 1.61) 0.393
Interaction entropy 0.47 (0.27, 0.82) 0.007 0.81 (0.52, 1.27) 0.359
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cut-offs are tested and the p value is adjusted to account for 
the bias of multiple testing. Stratification of OS based on the 
diversity of phenotypes was significant (Contal & O’ Quig-
ley [41] adjusted p = 0.032), assigning 45.6% of patients to 
the poor prognostic group.
Even though the diversity biomarkers predicted favour-
able OS, no associations were observed with PFS (Tables 1, 
2) and POD24 (Table 3, Fig. 3).
Discussion
This study introduced a 6-plex immunofluorescence protocol 
for concurrent observation of immune subsets and an image 
analysis pipeline to accurately detect cell types and objec-
tively measure tumour microenvironment diversity. This 
new approach provides a versatile and adaptable platform 
that could be extended to other tumour types. The proposed 
pipeline benefits from precise marker localisation as well as 
conservation of valuable tissue material through multiplex-
ing. The improved accuracy and reliability of quantitative 
immunofluorescence compared to conventional immunohis-
tochemistry, and its cost-effectiveness compared to in situ 
hybridisation, provide scope and rationale for wider clinical 
adoption.
Developing baseline prognostic biomarkers for risk 
stratification is a major area of research in FL, driven by 
an urgent need to develop effective therapies capable of 
improving the outcomes of high-risk disease. Using this 
pipeline, we report that increased diversity of immune 
infiltrate populations and interactions in FL is potential 
biomarkers of favourable OS. Diversity was quantified 
through a novel approach using Shannon’s entropy, a met-
ric describing species biodiversity in ecological sciences. 
The diversity of spatial interactions remained significant 
after Bonferroni correction for multiple comparisons in 
multivariable analysis of OS. Therefore, this biomarker 
could improve risk stratification, offering additional prog-
nostic value when combined with FLIPI assessment. The 
diversity biomarkers also outperformed simple cell den-
sity measurements. Indeed, none of the immune infiltrate 
cell densities remained significantly associated with sur-
vival endpoints in multivariable analysis (Table 2), simi-
lar to results reported by others [14] for rituximab-treated 
patients. This evidence supports applicability of the diver-
sity biomarker for risk stratification in FL.
Survival analysis (Tables 1, 2, 3) in this study treated all 
variables as continuous, to avoid the loss of information from 
arbitrary dichotomisation [43]. However, since dichotomisa-
tion is sometimes required for clinical decision-making, we 
also carried out Kaplan–Meier analysis by selecting a cut-
off to split the patients in two groups. Clinical studies often 
select the median or quartiles as the cut-off, even though is 
no underlying statistical reasoning for this selection [44]. 
We adopted the Contal and O’Quigley approach [40], as it 
provides a non-arbitrary cut-off selection and supplies a cor-
rected p value, taking into account the inflated type-I error 
that may result from testing multiple cut-offs. Further vali-
dation of this cut-off in additional cohorts would be benefi-
cial. However, since we performed Cox regression analyses 
Table 2  Multivariable survival analysis for features derived from the tumour microenvironment
Only subset of patients with available FLIPI data at diagnosis is included. HR hazard ratio; CI confidence intervals; PH proportional hazards; OS 
overall survival; PFS progression free survival. *The log rank test p value examines whether the null hypothesis of no effect (H0: HR = 1) can be 
rejected. Features are assessed as continuous variables. †Immune infiltrate ratio is calculated as the total immune cells (positive for any marker) 
divided by the number of cells that expressed only DAPI. P values ≤ 0.05 are shown in bold. P values ≤ 0.005 remain significant after the Bon-
ferroni correction for multiple hypothesis testing
Multivariable Models with FLIPI Cox PH Multivariable OS Cox PH Multivariable PFS
All Patients, N = 101, 20 events Rituximab Patients, N = 51, 29 
events
HR (95% CI) P* HR (95% CI) P*
Cell density, cells/mm2 CD4+CD68− T-helper cells 0.872 0.872 1 (1, 1) 0.158
CD4+FOXP3+ T-regs 0.96 (0.92, 1) 0.066 0.98 (0.95, 1) 0.109
CD8+ T-cells 1 (0.99, 1) 0.315 1 (0.99, 1) 0.561
CD68+ cells 0.99 (0.98, 1) 0.013 0.99 (0.99, 1) 0.046
CD4+CD68−PD-1+ 1 (0.98, 1.01) 0.478 1 (0.99, 1.01) 0.907
CD8+PD-1+ 0.97 (0.94, 1.01) 0.137 1 (0.98, 1.01) 0.613
Cell Ratio Immune infiltrate  ratio† 0.37 (0.07, 2) 0.247 0.35 (0.09, 1.37) 0.131
% Positive Area CD21+ dendritic meshwork area 0.4 (0.09, 1.69) 0.212 1.08 (0.25, 4.79) 0.915
Diversity, natural digits Phenotype entropy 0.19 (0.06, 0.65) 0.008 0.85 (0.31, 2.31) 0.750
Interaction entropy 0.39 (0.2, 0.75) 0.005 0.9 (0.53, 1.53) 0.700
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without dichotomising the variables, the reported prognostic 
value does not rely upon a specific cut-off selection.
Previous studies investigating tumour immune microen-
vironment diversity in other types of cancer have demon-
strated the importance of diversity in T-cell populations, as 
measured by T-cell receptor (TCR) next-generation (NGS) 
sequencing, in a way that is agnostic to the types of T-cells 
that are quantified [45]. Increased TCR diversity has been 
associated with improved clinical benefit in metastatic mel-
anoma [46] and favourable overall survival in metastatic 
breast cancer [47]. Furthermore, clonal TCR diversity has 
been shown to increase after immunotherapy treatments (e.g. 
cryo-immunotherapy for breast cancer [46] and Sipuleucel-
T immunotherapy for prostate cancer [48]) and is investi-
gated as a potential endpoint for response to therapy [47]. A 
diverse T-cell repertoire is thought to increase the likelihood 
that a useful anti-tumour T-cell population is present [46], 
leading to favourable outcomes. In this study we expand 
the concept of diversity to include T-cells and macrophages 
and propose that a diverse repertoire of immune cells in the 
microenvironment of FL could similarly increase the likeli-
hood of relevant anti-tumour pathways being active.
In this study,  CD68+ macrophages were significantly 
correlated with favourable OS in univariable analysis. A 
favourable trend of increased  CD68+ density was observed 
for PFS and POD24. This effect could be attributed to one 
of the mechanisms of action of the anti-CD20 rituximab 
treatment, whose immune-mobilising effects include the 
induction of antibody-dependent cell phagocytosis [49]. 
Consequently, cells coated with rituximab are recognised 
Fig. 3  Differences in immune cell density and tumour microenvironment diversity between POD24-positive and POD24-negative subgroups. 
Cell densities are shown in cells/mm2, while Shannon entropy is presented in natural bit units
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by macrophages as targets and killed [50]. The favourable 
effect of macrophages has been previously demonstrated in 
a rituximab-treated cohort [10]. However, this effect depends 
strongly on the type of treatment, as in cohorts treated with-
out rituximab [9, 11] increased numbers of tumour-associ-
ated macrophages correlated with unfavourable outcome.
To ensure reproducibility of results, we quantitatively 
validate the staining assay and cell detection algorithms 
and share publicly the image dataset [28]. The FL cohort 
included treatment pathways and prognostic outcomes 
reflective of current modern practice. The TMA tech-
nology employed is equivalent to whole section assess-
ments in lymphomas [51], enabling rapid processing 
of large number of samples. Furthermore, the diversity 
metrics demonstrated low intra-patient heterogeneity 
Table 3  Logistic regression for POD24 prediction in the subset treated with rituximab containing regimens
POD24 indicates disease progression within 24 months of starting treatment; OR indicates odds ratio. Only subset of patients with available 
FLIPI data at diagnosis is included in multivariable analysis and features treated as continuous variables. *The log rank test p value examines 
whether the null hypothesis of no effect (H0: odds ratio = 1) can be rejected. †Immune infiltrate ratio is calculated as the total immune cells (pos-
itive for any marker) divided by the number of cells that expressed only DAPI. Features are assessed as continuous variables. P values ≤ 0.05 are 
shown in bold. P values ≤ 0.005 would remain significant after the Bonferroni correction for multiple hypothesis testing
Logistic Regression for POD24 Univariable Multivariable with FLIPI
Rituximab patients, N = 67 [14 
events]
Rituximab patients, N = 51 [8 
events]
OR (95% CI) P* OR (95% CI) P*
Cell density, cells/mm2 CD4+CD68− T-helper cells 0.99 (0.99, 1) 0.027 0.99 (0.98, 1) 0.034
CD4+FOXP3+ T-regs 0.95 (0.9, 1) 0.066 0.95 (0.88, 1.02) 0.132
CD8+ T-cells 1 (0.99, 1.01) 0.465 1 (0.99, 1.01) 0.638
CD68+ cells 0.99 (0.98, 1) 0.051 0.98 (0.97, 1) 0.063
CD4+CD68−PD-1+ 0.98 (0.96, 1.01) 0.116 0.96 (0.92, 1.01) 0.100
CD8+PD-1+ 0.98 (0.95, 1.02) 0.389 0.97 (0.92, 1.04) 0.410
Cell ratio Immune infiltrate  ratio† 0.02 (0, 0.48) 0.017 0.01 (0, 1.23) 0.060
% Positive area CD21+ dendritic meshwork area 0.28 (0.02, 3.65) 0.334 0.06 (0, 3.14) 0.166
Diversity, natural digits Phenotype entropy 0.73 (0.13, 4.07) 0.718 0.64 (0.08, 5.07) 0.669
Interaction entropy 0.82 (0.33, 2.02) 0.665 0.75 (0.25, 2.27) 0.610
Fig. 4  Kaplan–Meier survival analysis. Analysis shown for OS, 
where patients have been split into two groups based on the optimal 
cut points. Cut points were selected using the Contal & O’Quigley 
test [38] method.  PLog Rank: significance for the log rank test and  PC.O.: 
significance for the Contal & O’Quigley test [38], adjusted for the 
fact that the optimal cut point has been selected to maximise separa-
tion of patient groups. Shaded areas represent 95% confidence inter-
vals [42]. a Effect of Shannon phenotype entropy (diversity) on OS; b 
effect of HID spatial “interaction” entropy (diversity) on OS
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(CoV = 7.7–8.3%), indicating robustness when assessed 
using triplicate TMA core samples.
A limitation of this study is the use of a single cut-off 
to score positive and negative cells for each stain. Robust 
cut-offs were selected by two different users of the com-
puter-assisted scoring system. However, this approach may 
sometimes underperform because of the inherent varia-
tion of staining intensities in positive cells. Notably, in 
FL two functionally different PD-1+ cell phenotypes have 
been observed [20], characterised by different levels of 
PD-1 expression: PD-1+high T follicular helper cells found 
inside the follicles actively support FL B-cell growth, while 
the PD-1+low cells found outside the follicles represent 
exhausted T-cells. The PD-1+ T-helper cells found within 
the follicles are also known to express CD4 less strongly 
(30.7% lower CD4 intensity) compared to other  CD4+ cells 
in the interfollicular areas [52]. The present study attempted 
to select single cut-offs able to pick up both the weakly and 
strongly positive cells. Use of multiple cut-offs was avoided 
as nuanced intensity variations can be challenging to cap-
ture using manual gating in a reproducible manner. Future 
work could adopt automated clustering [53] of cells based 
on their intensities or rely on additional functional markers 
in the multiplex panel (e.g. TIM3 for exhausted phenotypes 
or CXCR5 for T follicular helper cells [20]) to differentiate 
between PD-1 subsets.
Cox regression for PFS and logistic regression for POD24 
in the rituximab-treated subset did not demonstrate sig-
nificant prognostic value for any of the immune infiltrate 
biomarkers. However, the limited size and variable treat-
ment increase the risk of false-negative results. Therefore, 
the effect of tumour microenvironment diversity on early 
relapse merits further investigation before it could be ruled 
out. A significantly lower total immune infiltrate ratio was 
observed in patients that had POD24, as seen in Fig. 3. Even 
though the causality underpinning this observation is not 
well understood, the total immune infiltrate ratio may be fur-
ther investigated as an indicator of POD24 that can be cal-
culated at baseline, before treatment has started. Additional 
markers of B-cells and particularly of FL B-cells would 
be beneficial for a meaningful study of the “DAPI only” 
cells. The lack of a FL tumour marker is a limitation of this 
study, which prioritised the analysis of the non-neoplastic, 
immune microenvironment. By assessing 7 markers (DAPI, 
CD4, CD8, CD68, FOXP3, CD21, PD-1), we have reached 
the limit in number of markers permitted by the multiplex 
staining and imaging platform used in this study.
In summary, automated assessment of immune infiltrate 
and its diversity, based on multiplex immunofluorescence, 
warrants further exploration for prognostic biomarker devel-
opment in FL. Future work may involve validation of diver-
sity measurements using orthogonal assays, such as gene 
expression profiling. This pipeline is ready to be tested in 
larger series, with the potential to significantly improve risk 
stratification and treatment adaptation for high-risk FL in 
the future.
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